Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st C.

Business Wire • Feb 19, 2026

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton as a Potential First-in-Class Therapy for Narcolepsy Type 1.

Business Wire • Feb 10, 2026

Takeda deepens AI drug discovery push with $1.7 billion Iambic deal

Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecule drugs targeting cancer and gastrointestinal diseases.

Reuters • Feb 9, 2026

Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK).

Benzinga • Feb 9, 2026

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Takeda that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

Business Wire • Feb 9, 2026

Japanese drugmakers slump after Trump unveils discount drug website

Shares of Japanese pharmaceutical companies slumped in early Tokyo trading on Friday after U.S. President Donald Trump's website offering discounted prescription medicines went live.

Reuters • Feb 6, 2026

Takeda Tests New Highs, But Struggles To Find Entyvio Successor

Takeda Pharmaceuticals is downgraded from buy to hold after reaching 52-week highs, with valuation no longer compelling. TAK's Q3 earnings were resilient despite US revenue declining 9.1%; margin improvement and international growth offset generic headwinds. Entyvio remains the key growth driver, but lack of pipeline blockbusters and US weakness limit near-term catalysts.

Seeking Alpha • Jan 30, 2026

Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript

Seeking Alpha • Jan 29, 2026

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance ha.

Business Wire • Jan 29, 2026

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency (PI). GAMMAGARD LIQUID ERC is a liquid immunoglobulin therapy that does not require reconstitution and has a low immunoglobulin A (IgA) content less than or equal t.

Business Wire • Jan 22, 2026